Compare Bristol-Myers Squibb Co (BMY) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs ProShares Ultra Gold ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.93 (market cap $129.94B), while ProShares Ultra Gold ETF trades at $52.49. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while ProShares Ultra Gold ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| BMY | UGL | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $85.62 |
52-Week Low | $42.60 | $34.37 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
UGL is trading at $52.81, up 2.13% with a bullish technical signal from moving averages, though oscillators show bearish divergence. The stock faces resistance at $53 with support at $51. Recent gold market strength from inflation data and geopolitical tensions provides positive momentum, though financial ratios remain unavailable for fundamental assessment.
The outlook for UGL appears cautiously optimistic given gold's recent performance, but investment decisions require verified financial data currently missing. Key risks include gold price volatility and reliance on broader commodity trends. Analyst consensus and institutional positioning data are needed for comprehensive evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
